Press Release: RAPT Therapeutics Deepens Expertise in Allergic Diseases With Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
RAPT Therapeutics Deepens Expertise in Allergic Diseases With Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
We're Not Very Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate
Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)
RAPT Therapeutics Analyst Ratings
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $10
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics Focuses on RPT904 Development in 2025
RAPT Therapeutics Q4 EPS $(1.14) Misses $(0.36) Estimate
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings
RAPT Therapeutics | 10-K: FY2024 Annual Report
RAPT Therapeutics | 8-K: RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Express News | RAPT Therapeutics Q4 Basic EPS USD -1.14
Express News | RAPT Therapeutics Q4 Operating Expenses USD 54.465 Million
Express News | RAPT Therapeutics Q4 Net Income USD -53.249 Million
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
Rapt Therapeutics Files to Sell 176.45M Shares of Common Stock for Holders
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $6
Analysts Are Bullish on Top Healthcare Stocks: RAPT Therapeutics (RAPT), GE Healthcare Technologies Inc (GEHC)
RAPT Therapeutics Plans Phase 2b Trials for RPT904